Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...

The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily Icotyde pill, is an interleukin-23 ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Johnson & Johnson (JNJ) stock is in focus as US approves its once-daily pill Icotyde developed with Protagonist Therapeutics ...

AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its ...

Psoriasis patients are stigmatized and can later develop debilitating arthritis. July 29, 2011— -- Reality star Kim Kardashian publicly revealed a nasty rash to her dermatologist on a recent ...